Pulmonary hypertension in osa-copd overlap.

Laura Smith*

Department of Pulmonary Medicine, University of South Florida, USA

Introduction

Understanding the complex interplay between respiratory conditions is critical in clinical practice. Research highlights the intricate relationship between sleep-disordered breathing and Pulmonary Hypertension (PH) in people living with Chronic Obstructive Pulmonary Disease (COPD). It emphasizes that sleep-related breathing issues can significantly worsen PH in COPD patients, leading to poorer outcomes and a diminished quality of life. What this really means is that effective management of sleep apnea is crucial for improving vascular function and overall patient prognosis in this population[1].

Moving deeper into the topic, a systematic review comprehensively delves into the Overlap Syndrome, which is the established coexistence of COPD and Obstructive Sleep Apnea (OSA). This review specifically focuses on its profound connection to PH, painting a clear picture of the clinical challenges involved. The findings underscore that patients presenting with this challenging overlap syndrome frequently develop PH, often requiring a highly tailored diagnostic and therapeutic approach due to the compounding and often synergistic detrimental effects of both conditions on the pulmonary vasculature[2].

Further exploring this dual pathology, a narrative review provides a detailed overview of PH specifically in individuals suffering from both COPD and OSA. This work underscores the complex interplay between chronic hypoxia, systemic inflammation, and adverse vascular remodeling. These factors collectively drive the development and progression of PH in these overlap syndrome patients, strongly advocating for integrated and holistic treatment strategies that address both underlying conditions[3].

Looking at broader cardiovascular implications, another significant narrative review examines the overlap syndrome – the troublesome combination of COPD and OSA – as a potent and significant risk factor for various cardiovascular diseases. It lucidly elucidates how the pervasive chronic hypoxia and persistent inflammation, inherently present in this syndrome, contribute to a cascade of systemic cardiovascular complications. This includes, but is not limited to, PH. This analysis importantly emphasizes the urgent need for early detection and comprehensive, multidisciplinary management to effectively mitigate these substantial cardiovascular risks[4].

Beyond the specific overlap, a fundamental understanding of the underlying mechanistic links between sleep apnea and PH is crucial for targeted interventions. One article thoroughly explores these mechanisms, detailing precisely how intermittent hypoxia, persistent sympathetic nervous system activation, endothelial dysfunction, and widespread systemic inflammation, all primarily triggered by sleep apnea, collectively contribute to the development and progression of pulmonary vascular remodeling. This eventually leads to increased pulmonary artery pressure, which can occur even in the apparent absence of other significant lung diseases[5].

In a focused review, the pathogenesis and various management strategies for PH within the specific context of Obstructive Sleep Apnea (OSA) are thoroughly discussed. This valuable piece clarifies how the characteristic intermittent hypoxia and subsequent reoxygenation cycles, hallmark features of OSA, are direct drivers of pulmonary vasoconstriction and vascular remodeling. It meticulously outlines current and emerging therapeutic approaches, particularly highlighting the pivotal role of Continuous Positive Airway Pressure (CPAP), as a primary intervention to effectively alleviate pulmonary artery pressure in these vulnerable patients[6].

A key study investigates the prevalence and characteristics of PH in patients with COPD, meticulously examining those both with and without co-existing OSA. The findings powerfully suggest that the presence of OSA significantly influences both the prevalence and severity of PH in COPD patients. This indicates a clear synergistic and detrimental effect of both conditions on the pulmonary vasculature, underscoring the critical importance of systematic screening for OSA in this high-risk population to prevent adverse outcomes[7].

Turning to therapeutic outcomes, important research specifically focuses on evaluating the impact of Positive Airway Pressure (PAP) therapy on PH in patients who tragically suffer from both COPD and OSA. The compelling findings indicate that consistent PAP treatment can lead to tangible improvements in pulmonary artery pressure and also enhance overall cardiovascular function in these complex overlap syndrome patients. This clearly underscores PAPs significant therapeutic potential in managing the combined and se-

***Correspondence to:** Laura Smith, Department of Pulmonary Medicine, University of South Florida, USA. E-mail: laura.smith@usf.edu

Received: 01-Jul-2025, Manuscript No. AAJPCR-25-216; **Editor assigned:** 03-Jul-2025, Pre QC No. AAJPCR-25-216 *(PQ)*; **Reviewed:** 23-Jul-2025, QC No. AAJPCR-25-216; **Revised:** 01-Aug-2025, Manuscript No. AAJPCR-25-216 *(R)*; **Published:** 12-Aug-2025, DOI: 10.35841/aajpcr-8.4.216

Citation: Smith L. Pulmonary hypertension in osa-copd overlap. J Pulmonol Clin Res. 2025;08(04):216.

vere burden of these chronic conditions[8].

Further clarifying the aggravating role of OSA, another study specifically investigates how OSA influences the severity of PH in individuals already diagnosed with COPD. The robust results demonstrate that co-existing OSA is often strongly associated with more severe PH in COPD patients. This convincingly suggests that OSA acts as a potent and independent aggravating factor for pulmonary vascular disease in this already vulnerable patient population, demanding focused clinical attention[9].

To conclude this overview, a single-center study meticulously examines the prevalence and identifies key risk factors for PH in patients with OSA, crucially differentiating between those with and without co-occurring COPD. The compelling findings from this study highlight that PH is indeed common in both patient groups. However, the critical presence of COPD alongside OSA significantly escalates both the risk and severity of PH, pointing decisively to distinct yet synergistic pathophysiological pathways that require careful consideration in diagnosis and management[10].

Conclusion

Research consistently shows a strong link between sleep-disordered breathing, particularly Obstructive Sleep Apnea (OSA), and Pulmonary Hypertension (PH), especially in individuals with Chronic Obstructive Pulmonary Disease (COPD). This relationship often leads to worse patient outcomes. The coexistence of COPD and OSA, termed Overlap Syndrome, is a significant concern. Patients with this syndrome frequently develop PH, requiring specialized diagnostic and treatment strategies. Chronic hypoxia, inflammation, and vascular remodeling from both conditions contribute to PH development and progression. OSA exacerbates PH severity in COPD patients, acting as an aggravating factor for pulmonary vascular disease. Mechanistic studies detail how intermittent hypoxia, sympathetic nervous system activation, endothelial dysfunction, and systemic inflammation triggered by sleep apnea contribute to pulmonary vascular remodeling and increased pulmonary artery pressure. Effective management of sleep apnea, including Positive Airway Pressure (PAP) therapy, is crucial. PAP treatment has shown to improve pulmonary artery pressure and overall cardiovascular function in Overlap Syndrome patients, highlighting its therapeutic potential. Early detection and comprehensive management of the overlap syndrome are vital to mitigate cardiovascular risks. The prevalence of PH is high in OSA patients, but co-occurring COPD significantly escalates the risk and severity, indicating distinct and synergistic pathophysiological pathways. This underscores the critical need for integrated treatment approaches for OSA in COPD patients.

References

1. Shinsaku B, Tetsuya H, Kazuhiro H. Sleep-disordered breathing and pulmonary hypertension in chronic obstructive pulmonary disease. *Respir Investig.* 2023;61:362-371.
2. Alexey T, Martina D, *Marianna T. Overlap Syndrome* (COPD and OSA) and Pulmonary Hypertension: A Systematic Review. J Clin Med. 2023;12:1588.
3. Ruojia L, Huai W, Yuhong S. Pulmonary hypertension in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: a narrative review. *Front Cardiovasc Med.* 2023;10:1229646.
4. Mona Z, Sepideh G, Omid K. The overlap syndrome of COPD and OSA as a risk factor for cardiovascular disease: *A narrative review. Heart Lung.* 2024;59:173-181.
5. Chibuike OE, Afolabi O, *Adeolu AA. Mechanistic links between sleep apnea and pulmonary hypertension. Front Cardiovasc Med.* 2023;10:1193359.
6. Wajiha K, Ajith N, *Munazza A. Pathogenesis and Management of Pulmonary Hypertension in Obstructive Sleep Apnea. Int J Environ Res Public Health.* 2023;20:3591.
7. Li-Yueh L, Chia-Yu W, Yun-Jui *C. Pulmonary Hypertension in Patients with Chronic Obstructive Pulmonary Disease with or Without Obstructive Sleep Apnea. J Clin Med.* 2022;11:7496.
8. Hong M, Wenshuo X, *Yutong W. Effect of positive airway pressure on pulmonary hypertension in patients with COPD and obstructive sleep apnea. Front Med* (Lausanne). 2022;9:1068800.
9. Gholamreza R, Seyedmohammad M, *Mohammad G. Impact of Obstructive Sleep Apnea on Severity of Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease. Acta Biomed.* 2022;93:e2022247.
10. Ruojia L, Qihua H, Huai W. The Prevalence and Risk Factors of Pulmonary Hypertension in Patients with Obstructive Sleep Apnea with or without Chronic Obstructive Pulmonary Disease: A Single-Center *Study. Front Cardiovasc Med.* 2021;8:687926.

Citation: *Smith L. Pulmonary hypertension in osa-copd overlap. J Pulmonol Clin Res. 2025;08(04):216.*